THJ-2201
Synthetic cannabinoid
From Wikipedia, the free encyclopedia
THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1][2][3][4]
Legal status
- CA: Schedule II
- DE: Anlage II (Authorized trade only, not prescriptible)
- UK: Class B
- US: Schedule I
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H21FN2O |
| Molar mass | 360.432 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.[5]
Pharmacology
THJ-2201 acts as a full agonist with a binding affinity of 1.34 nM at CB1 and 1.32 nM at CB2 cannabinoid receptors.[6]
Side effects
THJ-2201 has been linked to at least one hospitalization and death due to its use.[7]
Legal status
It is classified as a Schedule I controlled substance in the United States.[8]